SC
SEEL

Shay Capital’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Shay Capital’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3
Closed -$16K – 582
2020
Q4 		$16K Buy
+3
New +$11.8K ﹤0.01% 278

Other funds holding SEEL

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Shay Capital's SEEL Position: Q1 2021 in Review

Shay Capital sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2021, closing a stake of 3 shares — an estimated $16K sold.

Shay Capital first reported a position in SEEL in Q4 2020 and held it in 1 quarter. The position peaked at $16K in Q4 2020. 60 funds tracked by Wall St. Rank hold SEEL as of Q1 2021.

  • Shay Capital reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Shay Capital sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $16K.
  • Shay Capital first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Shay Capital's Seelos Therapeutics, Inc. Common Stock position peaked at $16K in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Shay Capital's 13F filing for Q1 2021, filed 13 Aug 2021.